Table 1.
Baseline characteristics of BRAF mutated NSCLC patients (n = 65).
| Characteristics | No. of patients (%) | ||
|---|---|---|---|
| All N = 65 | V600E n = 54 | Non-V600E n = 11 | |
| Age, years | |||
| Median | 58 | 57.5 | 58 |
| Range | 33–79 | 33–78 | 46–79 |
| Sex | |||
| Male | 31 (47.7) | 23 (42.6) | 8 (72.7) |
| Female | 34 (52.3) | 31 (57.4) | 3 (27.3) |
| ECOG PS | |||
| 0–1 | 56 (86.2) | 49 (90.7) | 7 (63.6) |
| ≥2 | 9 (13.8) | 5 (9.3) | 4 (36.4) |
| Smoking status | |||
| Non-smoker | 30 (46.2) | 28 (51.9) | 2 (18.2) |
| Former/current smoker | 35 (53.8) | 26 (48.1) | 9 (81.8) |
| Histology | |||
| Adenocarcinoma | 64 (98.5) | 53 (98.1) | 11 (100.0) |
| Others | 1 (1.5) | 1 (1.9) | 0 (0.0) |
| Stage at diagnosis | |||
| 0 | 1 (1.5) | 0 (0.0) | 1 (9.1) |
| I | 10 (15.4) | 9 (16.7) | 1 (9.1) |
| II | 5 (7.7) | 4 (7.4) | 1 (9.1) |
| IIIA | 3 (4.6) | 3 (5.6) | 0 (0.0) |
| IIIB-IV | 46 (70.8) | 38 (70.4) | 8 (72.7) |
| Co-occurring mutation | |||
| TP53 | 4 | 2 | 2 |
| PIK3CA | 6 | 6 | 0 |
| KRAS | 1 | 0 | 1 |
| NTRK1 | 1 | 1 | 0 |